ANAB - AnaptysBio, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $79.17 DETAILS

Stock News

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.34 per share a year ago.

Sep 21, 2026 02:35 PM • zacks.com

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.

Sep 21, 2026 12:15 PM • globenewswire.com

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.

Sep 01, 2026 12:15 PM • globenewswire.com

16,500 Shares in AnaptysBio, Inc. $ANAB Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board purchased a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,500 shares of the biotechnology company's stock, valued at approximately $1,114,000. Canada Pension Plan Investment Board owned

Sep 01, 2026 12:03 AM • defenseworld.net

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.

Aug 24, 2026 08:41 AM • zacks.com

AnaptysBio: The Royalty Waterfall Is About To Reverse

AnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M net cash, eliminating prior R&D burn. Jemperli royalties escalate with sales, and once the Sagard obligation is paid (expected by mid-2027), ANAB will retain high-margin, growing royalty streams.

Jul 28, 2026 08:10 PM • seekingalpha.com

AnaptysBio (NASDAQ:ANAB) Stock Price Up 5.3% – Still a Buy?

AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) rose 5.3% during mid-day trading on Friday. The company traded as high as $56.54 and last traded at $57.00. 47,244 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 753,749 shares. The stock had previously closed at $54.15. Analysts Set

Jul 19, 2026 12:02 AM • defenseworld.net

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

Jul 14, 2026 05:31 AM • zacks.com

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.

May 21, 2026 06:40 AM • zacks.com

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

May 19, 2026 06:55 AM • zacks.com

AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

May 14, 2026 06:55 AM • zacks.com

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

May 12, 2026 12:15 PM • globenewswire.com

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors.

May 11, 2026 05:15 AM • globenewswire.com

AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?

Does AnaptysBio, Inc. (ANAB) have what it takes to be a top stock pick for momentum investors? Let's find out.

May 06, 2026 09:01 AM • zacks.com

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.

May 05, 2026 06:41 AM • zacks.com

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET.

May 04, 2026 12:15 PM • globenewswire.com

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in New England Journal of Medicine (NEJM) Evidence1. The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), submitted to the U.S. Food and Drug Administration (FDA) with a target action date of December 12, 2026.

Apr 28, 2026 03:12 PM • prnewswire.com

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apr 28, 2026 07:06 AM • zacks.com

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apr 27, 2026 07:02 AM • zacks.com

AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Apr 27, 2026 05:20 AM • zacks.com